Further studies on TB-associated lung cancer are needed to confirm chemoresistance and improvement of treatment efficacy when an Arg-I inhibitor is used in combination with other drugs such as immune checkpoint inhibitors. This evidence concerns the gene LNCARGI and tuberculosis.